A commentary on diagnosis and treatment of renal cell cancer The Lancet with Bernadett Szabados and Matthew Young. It covers broad aspects of the disease as well as areas of controvacy. gbr01.safelinks.protection.outlook.com/?url=https%3A%…

5-year results of the hypo-FLAME trial on focal boost #SBRT for intermediate/high-risk #prostatecancer. Presented at #ESTRO24, it shows excellent biochemical disease-free survival (93%) & low toxicity with a 5-fraction SBRT schedule. 👉bit.ly/4dts3Bh #Radonc

Kudos to the authors Flor Verghote Valérie Fonteyne and others for demonstrating that increased awareness of #bladderpreservation w #radiotherapy as a ttt option can lead to greater use, mostly driven by patient preference! dovepress.com/radiotherapy-u…

ARPI in the salvage RT setting: what do we have, and what should we aim for? Thomas Zilli nature.com/articles/s4139…

Interesting paper on the use of ARPI in the salvage RT setting. This will also be discussed during #PROSCA24 🗓️ 29-30 Nov 2024 📍Vienna, Austria & online 🌐 Programme: prosca-bladdr.org/global-forum-o…

Looking forward to welcoming you again at #PROSCA24 #BLADDR24 #RENALC24 in Vienna OncoAlert 🙏 🗓️Check out our programme and register 👉 bit.ly/4cY6wA1 🥇Will be a great edition this year with amazing faculty & 1st edition of RENALC!

No difference in oncological outcomes between complete and incomplete TURBT for bladder cancer patients treated with chemoradiation. Maybe it is time to reconsider the TMT paradigm and go for a dual-modality treatment: radio + chemo.

Very nice Roger Li and Ashish M. Kamat, MD, MBBS 👏👏👏! However, I am puzzled that there is no mention of radiotherapy in this paper 🤔

📰 EMA approves enfortumab vedotin + pembrolizumab for 1st-line treatment of advanced UCa 👀 How would you treat this case w/ mets #BladderCancer ❓ 📲 bit.ly/4cLXRQM OncoAlert

Don't forget to register to the webinar 'The new treatment landscape of metastatic UCa'! Register here for free: bigmarker.com/zidis/UCa?loca… Join the faculty: Philippe Barthélémy Viktor Grünwald Sylvie Rottey Emmanuel Seront Bernadett Szabados

#PACE A published in European Urology! SBRT vs Radical prostatectomy. Spread the word #SBRT should be discussed with eligible patients ⁦Dr Shaun Tolan⁩ Alison Tree 💙⁩ ⁦Clive Peedell⁩ Dr. Andrew Loblaw⁩ ⁦Prof Emma Hall⁩ Prof Joe O'Sullivan⁩ authors.elsevier.com/sd/article/S03…

Finetuning the #BLADDR24 programme at #ESMO2024 with Organising Committee member Maria De Santis. 💡Curious about the congress highlights on #BladderCancer of 2024? There is still time to register and join us in Vienna on 27-28 November: mirrorsofmedicine.idloom.events/RenalcBladdrPr… OncoAlert

Outstanding talk from silke gillessen elegantly presenting PEACE-3 phase 3 trials first results. Adding 6 cycles of Ra223 to enzalutamide as first-line therapy for mCRPC showed significant rPFS improvement + significant OS benefit #ESMO24 ESMO - Eur. Oncology OncoAlert UroToday.com

Congratulations to silke gillessen and the team on the PEACE-3 study results! PEACE-3 trial shows a significant improvement in rPFS and OS with Enzalutamide + Ra223 in mCRPC with bone metastases. Time to SSE remained similar at 24 months (18%). #ESMO24 @oncoalert ESMO - Eur. Oncology

Perioperative durvalumab + neoadjuvant chemo & cystectomy in operable bladder cancer significantly delays (HR 0.68) event free survival and a 25% reduction in the risk of death. 10% ⬆️ pCR. It’s the 1st time immune therapy has an OS benefit in muscle invasive UC #ESM024 NEJM

Interim results of SunRISe-4: centrally confirmed pCR rates (ypT0N0) were 42% in cohort 1 (TAR-200 + CET; N=79) and 23% in cohort 2 (CET monotx; N=41). TRAEs were observed in 72% of pts in cohort 1 and 44% of pts in cohort 2. Presented by Andrea Necchi #BladderCancer #ESMO

Platinum Priority Editorial: All Biochemical Recurrences Are Equal, but Some Are More Equal than Others by Vérane Achard and Bertrand Tombal Read the Editorial here: buff.ly/3XnKHnt #UroSoMe #MedTwitter #Editorial #EurUrol

And don't forget the accompanying editorial w/ the Orwellian reference title: x.com/EUplatinum/sta… tombal Vérane Achard

Second #Stampede presentation today silke gillessen on metformin in M1HSPC. Borderline OS gain, ?more in HV disease. Significant metabolic gains all pts MRC Clinical Trials Unit at UCL The ICR

How is Clinical Practice Changing in Advanced #ProstateCancer Post #ESMO24 ?? Mirrors of Medicine invites you to a discussion around PEACE III with Fred Saad and tombal Wednesday October 2, 7pm CEST Registration Link: us02web.zoom.us/webinar/regist…